生物製藥第三方物流市場：2026-2032年全球市場預測（依產品類型、服務類型、溫度區域、運輸方式、包裝類型及最終用戶分類）

預計到 2025 年，生物製藥第三方物流(3PL) 市值將達到 1,400.3 億美元，到 2026 年將成長至 1,610.4 億美元，到 2032 年將達到 3,842.3 億美元，複合年成長率為 15.51%。

主要市場統計數據
基準年 2025	1400.3億美元
預計年份：2026年	1610.4億美元
預測年份 2032	3842.3億美元
複合年成長率 (%)	15.51%

權威的策略概述揭示了為什麼專業的物流能力對於維持生物製藥的品質和使其進入市場至關重要。

生物製藥生命週期越來越依賴專業的第三方物流(3PL) 服務，以維護產品完整性、確保合規性並加快時效性要求高的交付。隨著先進治療方法、溫度敏感型生物製藥和複雜供應鏈的不斷擴展，相關人員必須應對一個以技術創新、監管和不斷變化的貿易趨勢為特徵的環境。

數位遙測、包裝技術創新、製造地搬遷以及日益嚴格的監管要求如何重新定義物流供應商的戰略重點。

生物物流第三方物流 (3PL) 產業正經歷一場變革，其驅動力包括技術成熟、監管改革以及製造地的轉型。數位化正從先導計畫走向實際應用，成為營運的核心功能，透過即時遙測、基於狀態的異常管理和預測分析，實現主動干預，從而減少廢棄物並加快出貨速度。

該評估旨在評估 2025 年關稅調整如何促使整個生物製藥供應鏈投資於近岸外包、最佳化運輸方式、提升海關專業知識和增強韌性。

源自於2025年美國貿易政策的關稅調整所帶來的累積影響，正切實重塑生物製藥供應鏈中的跨境物流流動和戰略物流決策。隨著關稅相關成本風險的顯現，許多製造商和物流合作夥伴正在重新評估籌資策略、庫存結構和運輸方式選擇，以在遵守海關和貿易法規的同時，維持盈利能力和服務水準。

詳細的細分框架揭示了服務類型、溫度區域、運輸方式、最終用戶需求、產品類型和包裝選擇如何共同決定物流策略。

細分市場分析揭示了服務結構、溫度控制要求、運輸方式、終端用戶畫像、產品類型和包裝選擇如何相互交織，共同界定物流供應商的價值提案和營運重點。從服務類型角度來看，市場涵蓋配送管理、包裝和貼標、運輸以及倉儲。包裝和貼標本身又分為主動式和被動式兩種方法，其中主動式包裝進一步細分為氣調包裝和冷藏集裝箱。運輸方式分為空運、鐵路運輸、公路運輸和海運，空運根據緊急程度和成本之間的權衡提供快遞和標準兩種選擇。倉儲需要在常溫儲存和冷藏保管容量之間取得平衡，並且必須在檢驗的監控系統下運作。

美洲、歐洲、中東和非洲以及亞太地區的基礎設施、管理體制和商業性趨勢的區域差異如何導致網路設計和服務優先事項的差異。

區域趨勢對網路設計和服務預期有顯著影響，每個區域都有其獨特的營運、監管和商業考量。在美洲，密集的創新叢集、先進的低溫運輸基礎設施和成熟的法規環境正在推動對高頻快遞服務、檢驗的冷藏保管和綜合海關專業知識的需求。區域貿易協定和國內製造業投資決定了運輸方式和倉庫位置，而商業客戶則優先考慮關鍵藥品的快速補充和可擴展的溫控倉儲。

市場領導之所以能夠成功，是因為他們結合了數位可視性、檢驗的低溫運輸資產、監管專業知識以及擴充性的商業模式。

生物製藥第三方物流(3PL) 產業的主要企業正從多個方面實現差異化：整合的數位化視覺性、檢驗的低溫運輸資產、法規和海關專業知識，以及能夠適應臨床產品和商業產品之間細微差異的靈活商業模式。市場領導者正在投資遙測平台，以產生持續的狀態資料並實現自動化異常管理，同時也拓展地域佈局，將庫存部署在更靠近關鍵需求點的位置。

為物流領導者提供切實可行的行動方案，以提高透明度、最佳化包裝策略、重新設計彈性網路，並將貿易合規性融入服務交付中。

產業領導者應優先採取一系列切實可行的措施，為生物製藥產業建立穩健、合規且經濟高效的第三方物流(3PL) 能力。首先，投資建置端到端視覺化系統，該系統應具備即時遙測、自動異常警報和整合報告功能，以滿足營運需求和監管要求。此類系統將減少產品損失，並在出現偏差時支援快速決策。

透過嚴格的混合方法，結合對從業者的訪談、對營運案例的審查、精心挑選的第二手資料的整合以及專家的同行評審，我們獲得了對物流的實用見解。

本分析所依據的研究採用了一種多方面的方法，結合了初步訪談、二手文獻整合以及營運案例研究，以確保其可靠性和相關性。關鍵資料來源包括與供應鏈和品管主管、物流營運人員、包裝工程師和監管專家進行的結構化訪談，這些訪談為能力差距和新實踐的定性評估提供了基礎。基於這些訪談，我們針對不同服務類型和地區進行了情境分析和風險映射。

檢驗的低溫運輸能力、高度適應性的網路以及一體化的貿易合規性是我們獲得競爭優勢和業務永續營運。

技術創新、日益嚴格的監管以及不斷變化的貿易格局正在加速生物物流第三方物流的發展。擁有先進遙測技術、檢驗的包裝生態系統以及深厚的法規和海關專業知識的供應商，將在產品要求複雜、對溫度敏感且服務期望高昂的市場中佔據優勢。在這種環境下，低溫運輸營運的卓越戰術性將直接轉化為製造商和醫療服務提供者的策略價值。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席體驗長觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 上市策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物製藥第三方物流市場：依產品類型分類

• 細胞療法
  • 樹突細胞療法
  • 幹細胞療法
• 基因治療
• 單株抗體
• 重組蛋白
• 疫苗
  • 失活
  • 活病毒疫苗

第9章：生物製藥第三方物流市場：依服務類型分類

• 分銷管理
• 包裝和標籤
  • 活性包裝
    • 氣調包裝
    • 冷藏貨櫃
  • 標籤服務
  • 被動式包裝
• 運輸
  • 空運
    • 航空快遞
    • 普通航空郵件
  • 鐵路運輸
  • 陸路交通
  • 海上運輸
• 倉儲
  • 室溫儲存倉庫
  • 冷藏倉庫

第10章：按溫度區域分類的生物製藥第三方物流市場

• 環境的
• 冷藏
  • 冷藏並監控
  • 標準冷凍
• 管制室溫
  • 受控室溫（帶監控）
  • 標準控制室溫
• 冰凍
  • 標準冷凍
  • 超低溫

第11章：生物製藥第三會物流市場：依交通途徑

• 空運
  • 航空快遞
  • 普通航空郵件
• 鐵路貨運
• 陸路交通
  • 整車裝載
  • 小件貨物
• 海上運輸
  • 整箱貨
  • 小批量貨櫃運輸

第12章：生物製藥第三方物流市場：依包裝類型分類

• 活性包裝
  • 冷藏貨櫃
  • 溫控運輸容器
• 被動式包裝
  • 保溫箱
  • 保溫毯

第13章：生物製藥第三方物流市場：依最終用戶分類

• 生物製藥製造商
• 契約製造組織
• 合約研究組織（CTA）
• 診斷檢測實驗室
• 醫院和診所
  • 當地醫院
  • 研究醫院

第14章：生物製藥第三會物流市場：依地區分類

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第15章：生物製藥第三方物流市場：依組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第16章：生物製藥第三方物流市場：依國家分類

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第17章：美國生物製藥第三方物流市場

第18章：中國生物製藥第三方物流市場

第19章 競爭情勢

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• Agility Public Warehousing Company KSCP
• Bollore SE
• CH Robinson Worldwide, Inc.
• Cardinal Health, Inc.
• Cencora, Inc.
• CEVA Logistics AG
• Cryoport, Inc.
• DB Schenker Logistics Germany AG & Co. KG
• Deutsche Post AG
• DSV Panalpina A/S
• EVERSANA Life Science Services LLC
• Expeditors International of Washington, Inc.
• FedEx Corporation
• KLN Logistics Group Limited
• Kuehne+Nagel International AG
• LOGISTEED, Ltd.
• McKesson Corporation
• NIPPON EXPRESS HOLDINGS, INC.
• SF Holding Co., Ltd.
• Thermo Fisher Scientific Inc.
• United Parcel Service, Inc.
• XPO, Inc.

The Biopharmaceutical Third Party Logistics Market was valued at USD 140.03 billion in 2025 and is projected to grow to USD 161.04 billion in 2026, with a CAGR of 15.51%, reaching USD 384.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 140.03 billion
Estimated Year [2026]	USD 161.04 billion
Forecast Year [2032]	USD 384.23 billion
CAGR (%)	15.51%

An authoritative strategic overview highlighting why specialized logistics capabilities are mission-critical for preserving biopharmaceutical product integrity and enabling market access

The lifecycle of biopharmaceutical products increasingly depends on specialized third-party logistics capabilities that preserve integrity, ensure regulatory compliance, and expedite time-critical deliveries. As advanced therapies, temperature-sensitive biologics, and complex supply chains proliferate, stakeholders must navigate a landscape defined by technological innovation, regulatory scrutiny, and evolving trade dynamics.

This report synthesizes operational realities and strategic inflection points for logistics partners and their customers across research, clinical, and commercial channels. It examines how service design, temperature control, transportation modes, packaging sophistication, and end-user needs interact to shape operational priorities. The analysis highlights where providers can extract value through capability investment, process standardization, and risk mitigation.

Importantly, the executive summary is intended to equip senior leaders with a concise yet comprehensive perspective that informs procurement, network design, and partnership strategies. By foregrounding the most consequential trends and decision levers, this synthesis aims to catalyze targeted investments that reduce product loss, accelerate patient access, and improve total cost-to-serve without compromising quality or compliance.

Readers will find pragmatic insights that support cross-functional collaboration between supply chain, quality, regulatory, and commercial teams. The objective is to frame the strategic choices logistics stakeholders must make today to remain resilient and competitive in a sector where scientific and regulatory complexity continue to rise.

How digital telemetry, packaging innovation, manufacturing redistribution, and elevated regulatory expectations are collectively redefining strategic priorities for logistics providers

The biopharmaceutical third-party logistics landscape is undergoing transformative shifts driven by technological maturation, regulatory recalibration, and changing manufacturing footprints. Digitalization is moving beyond pilot projects into operational core functions, with real-time telemetry, condition-based exception management, and predictive analytics enabling proactive interventions that reduce spoilage and expedite shipments.

Simultaneously, packaging innovation is reshaping cold chain economics. Active packaging solutions such as controlled atmosphere systems and advanced refrigerated containers are increasingly deployed alongside sophisticated passive insulation to create hybrid models that extend viable transit windows and reduce reliance on expedited modes. These technical advances are complemented by tighter integration between packaging design and transportation planning, which together optimize payload density and lower per-unit handling risks.

Another key vector of transformation is the strategic redistribution of manufacturing and supply nodes. The acceleration of regional manufacturing hubs and increased verticalization among biopharmaceutical firms are prompting logistics providers to reconfigure networks toward nearshoring and multi-node distribution. These shifts require flexible warehousing footprints combining ambient and cold storage capabilities and tailored transportation solutions spanning express air, standard air, sea freight, and road modalities.

Regulatory scrutiny is intensifying, and compliance expectations are expanding from documentation accuracy to demonstrable end-to-end control through digital audit trails and validated temperature control systems. As a result, providers that can demonstrate robust quality systems, validated processes, and transparent chain-of-custody reporting will capture greater trust and market preference. In short, the industry is moving toward an ecosystem where technological capability, regulatory readiness, and network adaptability determine market leadership.

Assessing how 2025 tariff adjustments have triggered nearshoring, modal optimization, enhanced customs expertise, and resilience investments across biopharmaceutical supply chains

The cumulative effects of tariff adjustments originating from United States trade policy in 2025 are materially reshaping cross-border flows and strategic logistics decision-making for biopharmaceutical supply chains. Tariff-driven cost exposure has prompted many manufacturers and logistics partners to reassess sourcing strategies, inventory postures, and modal choices in order to preserve margin and service levels while maintaining compliance with customs and trade rules.

One immediate consequence is the intensification of nearshoring discussions. Companies are increasingly evaluating whether to relocate certain production steps or hold buffer inventories in closer proximity to key markets to reduce the incidence of tariff-triggered cost spikes. This tactical shift has downstream implications for warehousing strategies, requiring flexible contract terms and the ability to scale cold and ambient storage on short notice.

Trade barriers have also incentivized modal reassessment. When tariffs raise the landed cost of ocean-shipped intermediate inputs or finished goods, organizations may switch to higher-cost but faster air transport for critical SKUs to mitigate exposure, or conversely consolidate volumes and optimize containerization strategies to amortize duties over larger shipments. Both approaches demand enhanced coordination between packaging design and transportation planning to maintain temperature integrity while managing per-shipment economics.

Customs complexity and documentation scrutiny have increased in tandem with tariff changes, elevating the importance of trade compliance expertise within third-party logistics offerings. Providers that can deliver customs brokerage competence, tariff classification advisory, and duty mitigation services add strategic value. Moreover, tariff volatility has underscored the importance of contractual flexibility around pass-through costs, hedging arrangements, and service-level adjustment clauses so that commercial relationships remain equitable under shifting trade conditions.

Beyond cost management, tariffs have accelerated investments in supply chain visibility and scenario planning. Organizations now place greater emphasis on stress-testing distribution networks against tariff escalations and simulating their operational impact on lead times, inventory days of supply, and cold chain continuity. This greater focus on resilience translates into demand for analytics-driven consulting and a willingness to invest in dual-sourcing, buffer warehousing, and modular transportation capacity that can be redeployed as trade dynamics evolve.

A detailed segmentation framework exposing how service types, temperature classifications, transport modes, end-user demands, product categories, and packaging choices jointly determine logistics strategy

Segmentation analysis reveals how service structures, temperature control requirements, transportation modes, end-user profiles, product types, and packaging choices intersect to define value propositions and operational priorities for logistics providers. When examined through the lens of service type, the market encompasses distribution management, packaging and labeling, transportation, and warehousing. Packaging and labeling itself splits into active and passive approaches, with active packaging further differentiating into controlled atmosphere solutions and refrigerated containers. Transportation subdivides into air, rail, road, and sea, with air offering express and standard options that cater to different urgency and cost trade-offs. Warehousing balances ambient storage with cold storage capabilities that must operate under validated monitoring regimes.

Temperature range segmentation drives core operational decisions because ambient, chilled, controlled room temperature, and frozen conditions each impose distinct handling, monitoring, and regulatory requirements. The chilled segment distinguishes between monitored chilled and standard chilled environments, while controlled room temperature operations are similarly differentiated by monitored and standard variants; frozen logistics separates standard frozen from ultra-frozen requirements that often necessitate specialized infrastructure.

Mode-of-transportation segmentation highlights how choice of air freight, rail freight, road transport, and sea freight affects transit time, environmental exposure, and packaging demands. Air freight options include express and standard air, road transport distinguishes between full truck load and less-than-truckload models, and sea freight differentiates between full container load and less-than-container load strategies. These modal distinctions inform optimal packaging and inventory strategies across the distribution footprint.

End-user segmentation clarifies demand heterogeneity: biopharmaceutical manufacturers, contract manufacturing organizations, contract research organizations, diagnostic laboratories, and hospitals and clinics each generate different service-level expectations and regulatory touchpoints. Hospitals and clinics further split into community hospitals and research hospitals, which diverge in procurement cadence and clinical risk tolerance.

Product-type segmentation identifies unique handling needs across cell therapies, gene therapies, monoclonal antibodies, recombinant proteins, and vaccines. Cell therapies require sub-segmentation into dendritic cell therapies and stem cell therapies, each with intense cold chain sensitivity. Vaccines divide into inactivated and live attenuated types, which carry different stability, transport, and regulatory demands. Finally, packaging type segmentation contrasts active and passive systems; active packaging includes refrigerated containers and temperature-controlled shippers while passive solutions rely on insulated boxes and thermal blankets. Together, these segmentation axes form a matrix that governs infrastructure investment, personnel training, and quality assurance protocols for third-party logistics providers.

How distinct regional infrastructure, regulatory regimes, and commercial dynamics across the Americas, EMEA, and Asia-Pacific drive differentiated network design and service priorities

Regional dynamics materially influence network design and service expectations, with each geography presenting distinct operational, regulatory, and commercial considerations. In the Americas, dense innovation clusters, advanced cold chain infrastructure, and a mature regulatory environment create demand for high-frequency express services, validated cold storage, and integrated customs expertise. Regional trade agreements and domestic manufacturing investments shape modal choices and warehouse placement, while commercial customers prioritize rapid replenishment for critical therapies and scalable temperature-controlled warehousing.

Europe, the Middle East, and Africa present a heterogeneous set of conditions. Western Europe combines strict regulatory oversight with established multimodal corridors, encouraging providers to deploy harmonized quality management systems and cross-border cold chain solutions. The Middle East functions as a hub for distribution and re-export, prompting investments in transit-oriented warehousing and resilient air connectivity. Africa introduces infrastructural and cold chain challenges that increase the importance of last-mile solutions, partnership models with local operators, and investments in passive packaging to mitigate limited refrigerated capacity.

Asia-Pacific offers a blend of high-volume manufacturing centers, rapidly expanding regional demand, and variable regulatory environments. Southeast Asia and parts of South Asia are seeing accelerated capacity build-out for both ambient and cold storage, while Northeast Asia continues to drive high-complexity exports of biologics that demand rigorous temperature control and expedited transport options. Across the region, logistics providers must balance investment in large-scale cold chain assets with agile distribution networks that can adapt to fluctuating trade flows, regulatory differences, and seasonal demand patterns.

Why market leaders succeed through a combination of digital visibility, validated cold chain assets, regulatory expertise, and flexible, scalable commercial models

Leading companies in the third-party logistics space for biopharmaceuticals are differentiating along several axes: integrated digital visibility, validated cold chain assets, regulatory and customs expertise, and flexible commercial models that accommodate clinical and commercial product nuances. Market leaders invest in telemetry platforms that generate continuous condition data and enable automated exception management, while simultaneously expanding geographically to position inventory closer to key demand centers.

Strategic partnerships and acquisition activity are common routes to quickly acquire niche capabilities, such as ultra-low temperature storage or specialized packaging engineering. Providers that combine in-house technical know-how with scalable warehousing footprints and a network of certified carriers deliver a compelling proposition for manufacturers and service organizations seeking lower risk. In addition, firms that embed trade compliance and tariff advisory into their service mix provide additional value as companies navigate complex cross-border flows.

Operational excellence remains a differentiator: companies that standardize procedures across regions, validate packaging and transport solutions, and maintain rigorous documentation practices reduce latency during regulatory inspections and audits. The ability to offer modular services-from dedicated cold rooms to managed distribution programs-enables logistics providers to address the spectrum of needs from contract research organizations to large-scale biopharmaceutical manufacturers. Ultimately, commercial success correlates with the ability to translate technical capability into predictable, auditable service performance.

Practical, high-impact actions for logistics leaders to enhance visibility, optimize packaging strategies, redesign networks for resilience, and integrate trade compliance into service delivery

Industry leaders should prioritize a set of actionable steps to build resilient, compliant, and cost-effective third-party logistics capabilities for biopharmaceutical products. First, invest in end-to-end visibility systems that provide real-time telemetry, automated exception alerts, and integrated reporting to satisfy both operational needs and regulatory requirements. Such systems reduce product loss and support rapid decision-making when deviations occur.

Second, adopt a layered packaging strategy that pairs passive and active solutions to optimize cost while protecting product integrity. By aligning packaging selection with transit modality and temperature sensitivity, organizations can extend delivery windows without consistently resorting to time-critical air shipments. This approach should be validated through protocol-driven qualification testing.

Third, re-evaluate network topology to incorporate nearshoring and multi-node distribution where appropriate. Reducing cross-border exposure and situating buffer inventory closer to demand can mitigate tariff risk and shorten lead times. However, any network redesign must be accompanied by contractual flexibility with service providers and contingency plans for capacity constraints.

Fourth, embed trade compliance and customs advisory into logistics partnerships to proactively manage tariff implications and classification risks. Providers that offer these capabilities remove a significant administrative burden from customers and improve predictability in landed cost management.

Finally, develop modular commercial offerings that permit rapid scaling between clinical and commercial phases, support ultra-cold storage needs, and provide dedicated customer success resources for high-risk product classes. Aligning commercial incentives with service reliability encourages collaborative problem-solving and long-term partnerships.

A rigorous mixed-methods research approach combining practitioner interviews, operational case reviews, selective secondary synthesis, and expert peer validation to produce actionable logistics insights

The research underpinning this analysis combines a multi-method approach that triangulates primary interviews, secondary literature synthesis, and operational case reviews to ensure robustness and relevance. Primary inputs include structured interviews with supply chain and quality executives, logistics operators, packaging engineers, and regulatory specialists, which inform qualitative assessments of capability gaps and emergent practices. These conversations formed the basis for scenario analysis and risk mapping across service types and regions.

Secondary sources were selectively reviewed to contextualize technological adoption patterns, regulatory developments, and modal cost dynamics. Operational case reviews provided granular insight into packaging qualifications, cold chain failures, and remediation strategies, enabling the identification of repeatable mitigations and best practices. Emphasis was placed on validated examples rather than anecdote, and care was taken to cross-check claims against multiple independent practitioner accounts.

To maintain analytical rigor, the methodology incorporated sensitivity testing of network and packaging assumptions, as well as peer review by subject matter experts with hands-on experience in biopharma logistics operations. The analysis avoids speculative forecasts and focuses on empirically grounded trends, observed behaviors, and practical implications for procurement and operations teams.

Limitations are acknowledged: the research emphasizes qualitative and operational insights rather than proprietary commercial metrics. Where appropriate, recommendations are framed for adaptation to specific contexts and include prompts for organizations to conduct localized validation and cost-benefit analysis prior to large-scale implementation.

Synthesis of why validated cold chain capabilities, adaptable networks, and embedded trade compliance will determine competitive advantage and operational resilience

The confluence of technological innovation, regulatory tightening, and shifting trade dynamics is accelerating the evolution of third-party logistics for biopharmaceuticals. Providers that cultivate advanced telemetry, validated packaging ecosystems, and deep regulatory and customs expertise will be best positioned to serve a market defined by complex product sensitivity and high service expectations. In this environment, tactical excellence in cold chain operations translates directly into strategic value for manufacturers and care providers alike.

Network adaptability and commercial flexibility emerge as central themes: the ability to repurpose warehousing footprints, pivot transportation modes, and offer modular service packages enables rapid response to both demand surges and policy disruptions. Companies that integrate trade compliance into their core offering reduce friction and add competitive differentiation, especially as tariff volatility and cross-border complexity persist.

Finally, the most successful logistics partners will be those that operationalize continuous improvement-systematically validating packaging, stress-testing distribution designs, and investing in workforce training to meet rising quality expectations. By translating insights into validated processes and demonstrable performance, logistics providers can reduce waste, accelerate patient access, and support the broader commercialization pathways of increasingly sophisticated biopharmaceutical therapies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopharmaceutical Third Party Logistics Market, by Product Type

• 8.1. Cell Therapies
  • 8.1.1. Dendritic Cell Therapies
  • 8.1.2. Stem Cell Therapies
• 8.2. Gene Therapies
• 8.3. Monoclonal Antibodies
• 8.4. Recombinant Proteins
• 8.5. Vaccines
  • 8.5.1. Inactivated
  • 8.5.2. Live Attenuated

9. Biopharmaceutical Third Party Logistics Market, by Service Type

• 9.1. Distribution Management
• 9.2. Packaging & Labeling
  • 9.2.1. Active Packaging
    • 9.2.1.1. Controlled Atmosphere Packaging
    • 9.2.1.2. Refrigerated Containers
  • 9.2.2. Labeling Services
  • 9.2.3. Passive Packaging
• 9.3. Transportation
  • 9.3.1. Air Transport
    • 9.3.1.1. Express Air
    • 9.3.1.2. Standard Air
  • 9.3.2. Rail Transport
  • 9.3.3. Road Transport
  • 9.3.4. Sea Transport
• 9.4. Warehousing
  • 9.4.1. Ambient Storage Warehousing
  • 9.4.2. Cold Storage Warehousing

10. Biopharmaceutical Third Party Logistics Market, by Temperature Range

• 10.1. Ambient
• 10.2. Chilled
  • 10.2.1. Monitored Chilled
  • 10.2.2. Standard Chilled
• 10.3. Controlled Room Temperature
  • 10.3.1. Monitored Controlled Room Temperature
  • 10.3.2. Standard Controlled Room Temperature
• 10.4. Frozen
  • 10.4.1. Standard Frozen
  • 10.4.2. Ultra Frozen

11. Biopharmaceutical Third Party Logistics Market, by Mode Of Transportation

• 11.1. Air Freight
  • 11.1.1. Express Air
  • 11.1.2. Standard Air
• 11.2. Rail Freight
• 11.3. Road Transport
  • 11.3.1. Full Truck Load
  • 11.3.2. Less Than Truck Load
• 11.4. Sea Freight
  • 11.4.1. Full Container Load
  • 11.4.2. Less Than Container Load

12. Biopharmaceutical Third Party Logistics Market, by Packaging Type

• 12.1. Active Packaging
  • 12.1.1. Refrigerated Containers
  • 12.1.2. Temperature Controlled Shippers
• 12.2. Passive Packaging
  • 12.2.1. Insulated Boxes
  • 12.2.2. Thermal Blankets

13. Biopharmaceutical Third Party Logistics Market, by End User

• 13.1. Biopharmaceutical Manufacturers
• 13.2. Contract Manufacturing Organizations
• 13.3. Contract Research Organizations
• 13.4. Diagnostic Laboratories
• 13.5. Hospitals & Clinics
  • 13.5.1. Community Hospitals
  • 13.5.2. Research Hospitals

14. Biopharmaceutical Third Party Logistics Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Biopharmaceutical Third Party Logistics Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Biopharmaceutical Third Party Logistics Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States Biopharmaceutical Third Party Logistics Market

18. China Biopharmaceutical Third Party Logistics Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. Agility Public Warehousing Company K.S.C.P.
• 19.6. Bollore SE
• 19.7. C.H. Robinson Worldwide, Inc.
• 19.8. Cardinal Health, Inc.
• 19.9. Cencora, Inc.
• 19.10. CEVA Logistics AG
• 19.11. Cryoport, Inc.
• 19.12. DB Schenker Logistics Germany AG & Co. KG
• 19.13. Deutsche Post AG
• 19.14. DSV Panalpina A/S
• 19.15. EVERSANA Life Science Services LLC
• 19.16. Expeditors International of Washington, Inc.
• 19.17. FedEx Corporation
• 19.18. KLN Logistics Group Limited
• 19.19. Kuehne + Nagel International AG
• 19.20. LOGISTEED, Ltd.
• 19.21. McKesson Corporation
• 19.22. NIPPON EXPRESS HOLDINGS, INC.
• 19.23. SF Holding Co., Ltd.
• 19.24. Thermo Fisher Scientific Inc.
• 19.25. United Parcel Service, Inc.
• 19.26. XPO, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 13. UNITED STATES BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 14. CHINA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STEM CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STEM CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 84. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 85. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 86. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 87. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 88. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 89. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
• TABLE 90. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 91. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 92. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 93. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 94. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 95. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 96. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
• TABLE 97. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 99. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 100. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 101. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 102. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 103. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 104. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 105. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
• TABLE 107. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 108. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 109. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 111. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 112. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 113. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 114. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 115. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 116. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
• TABLE 117. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 118. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 119. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 120. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 121. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 122. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 123. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
• TABLE 124. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 125. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 126. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 127. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, 2018-2032 (USD MILLION)
• TABLE 128. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 129. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 130. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 131. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 132. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 133. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 134. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 135. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 136. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 137. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 138. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 139. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 140. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, 2018-2032 (USD MILLION)
• TABLE 141. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY REGION, 2018-2032 (USD MILLION)
• TABLE 142. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 143. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 144. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY REGION, 2018-2032 (USD MILLION)
• TABLE 145. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 146. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 147. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 148. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 149. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 150. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, 2018-2032 (USD MILLION)
• TABLE 151. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY REGION, 2018-2032 (USD MILLION)
• TABLE 152. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 153. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 154. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY REGION, 2018-2032 (USD MILLION)
• TABLE 155. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 156. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 157. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
• TABLE 158. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 159. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 160. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 161. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
• TABLE 162. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 163. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 164. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 165. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE CONTROLLED SHIPPERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 166. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE CONTROLLED SHIPPERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 167. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE CONTROLLED SHIPPERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 168. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 169. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 170. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 171. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
• TABLE 172. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY INSULATED BOXES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 173. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY INSULATED BOXES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 174. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY INSULATED BOXES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 175. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY THERMAL BLANKETS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 176. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY THERMAL BLANKETS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 177. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY THERMAL BLANKETS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 178. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 179. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 180. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 181. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 182. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 183. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 184. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 185. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 186. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 187. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 188. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 189. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 190. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 191. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 192. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 193. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 194. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
• TABLE 195. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 196. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 197. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 198. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RESEARCH HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 199. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RESEARCH HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 200. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RESEARCH HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 201. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 202. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 203. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 204. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
• TABLE 205. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
• TABLE 206. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 207. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
• TABLE 208. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
• TABLE 209. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
• TABLE 210. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
• TABLE 211. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, 2018-2032 (USD MILLION)
• TABLE 212. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
• TABLE 213. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
• TABLE 214. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
• TABLE 215. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
• TABLE 216. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
• TABLE 217. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, 2018-2032 (USD MILLION)
• TABLE 218. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, 2018-2032 (USD MILLION)
• TABLE 219. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, 2018-2032 (USD MILLION)
• TABLE 220. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
• TABLE 221. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
• TABLE 222. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
• TABLE 223. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 224. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
• TABLE 225. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 226. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 227. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
• TABLE 228. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
• TABLE 229. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 230. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
• TABLE 232. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
• TABLE 234. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, 2018-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
• TABLE 236. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
• TABLE 238. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
• TABLE 240. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, 2018-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, 2018-2032 (USD MILLION)
• TABLE 242. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, 2018-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
• TABLE 244. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
• TABLE 245. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
• TABLE 246. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
• TABLE 248. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 249. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 250. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
• TABLE 252. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
• TABLE 254. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
• TABLE 255. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
• TABLE 256. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, 2018-2032 (USD MILLION)
• TABLE 258. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
• TABLE 260. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
• TABLE 261. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
• TABLE 262. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
• TABLE 263. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY